OptiNose Inc OPTN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OPTN is a good fit for your portfolio.
News
-
Optinose to Present at the Needham Virtual Healthcare Conference
-
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis
-
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
-
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
-
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
-
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
-
Optinose Shares Slide Premarket as FDA Extends Xhance Review
Trading Information
- Previous Close Price
- $0.93
- Day Range
- $0.89–0.97
- 52-Week Range
- $0.90–2.10
- Bid/Ask
- $0.93 / $0.95
- Market Cap
- $100.73 Mil
- Volume/Avg
- 653,599 / 625,688
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 132
- Website
- https://www.optinose.com
Comparables
Valuation
|
Metric
|
OPTN
|
INVA
|
SUPN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 8.95 | 107.37 |
Price/Book Value | — | 1.38 | 1.71 |
Price/Sales | 1.46 | 4.11 | 2.64 |
Price/Cash Flow | — | 7.69 | 13.33 |
Price/Earnings
OPTN
INVA
SUPN
Financial Strength
|
Metric
|
OPTN
|
INVA
|
SUPN
|
|---|---|---|---|
Quick Ratio | 0.53 | 7.28 | 1.38 |
Current Ratio | 0.60 | 9.03 | 1.70 |
Interest Coverage | −0.95 | 10.31 | −2.18 |
Quick Ratio
OPTN
INVA
SUPN
Profitability
|
Metric
|
OPTN
|
INVA
|
SUPN
|
|---|---|---|---|
Return on Assets (Normalized) | −30.10% | 14.79% | 2.53% |
Return on Equity (Normalized) | — | 29.29% | 4.09% |
Return on Invested Capital (Normalized) | −30.20% | 16.71% | 2.73% |
Return on Assets
OPTN
INVA
SUPN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Zksjkjgjq | Yxzs | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Lfgtswvqc | Wslsjpt | $68.1 Bil | |
HLN
| Haleon PLC ADR | Xwrtjzmrm | Ggtjs | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xstdvzbf | Lnsn | $14.3 Bil | |
VTRS
| Viatris Inc | Qwxxzzjh | Ymsrc | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Bctzfvjw | Mpwc | $11.9 Bil | |
CTLT
| Catalent Inc | Qyvxfsd | Fvtqwng | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Xqmggzndz | Sqf | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Zxwwvjwx | Lzyh | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vwhdgrvbx | Lhbxpk | $3.4 Bil |